Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Episodic ataxia type 1 Indication Strategy Report 2026: KCNA1, Trials and Deals
24 July 2026
2026 Episodic ataxia type 1 strategy: epidemiology, KCNA1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 12 Indication Strategy Report 2026: PPP2R2B, Trials and Deals
24 July 2026
2026 Spinocerebellar ataxia type 12 strategy: epidemiology, PPP2R2B biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 17 Indication Strategy Report 2026: TBP, Trials and Deals
24 July 2026
2026 Spinocerebellar ataxia type 17 strategy: epidemiology, TBP biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Spinocerebellar ataxia type 8 Indication Strategy Report 2026: ATXN8OS, Trials and Deals
24 July 2026
2026 Spinocerebellar ataxia type 8 strategy: epidemiology, ATXN8OS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Progressive familial intrahepatic cholestasis type 3 Indication Strategy Report 2026: MDR3, Trials and Deals
24 July 2026
2026 Progressive familial intrahepatic cholestasis type 3 strategy: epidemiology, MDR3 biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Microvillus inclusion disease Indication Strategy Report 2026: MYO5B, Trials and Deals
24 July 2026
2026 Microvillus inclusion disease strategy: epidemiology, MYO5B biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Progressive familial intrahepatic cholestasis type 2 Indication Strategy Report 2026: BSEP, Trials and Deals
24 July 2026
2026 Progressive familial intrahepatic cholestasis type 2 strategy: epidemiology, BSEP biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Progressive familial intrahepatic cholestasis type 1 Indication Strategy Report 2026: FXR, Trials and Deals
24 July 2026
2026 Progressive familial intrahepatic cholestasis type 1 strategy: epidemiology, FXR biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Congenital chloride diarrhea Indication Strategy Report 2026: SLC26A3, Trials and Deals
24 July 2026
2026 Congenital chloride diarrhea strategy: epidemiology, SLC26A3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Small intestinal bacterial overgrowth Indication Strategy Report 2026: Methanogen reductase, Trials and Deals
24 July 2026
2026 Small intestinal bacterial overgrowth strategy: epidemiology, Methanogen reductase biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
Perianal fistulizing Crohn disease Indication Strategy Report 2026: TNF, Trials and Deals
24 July 2026
2026 Perianal fistulizing Crohn disease strategy: epidemiology, TNF biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Ulcerative proctitis Indication Strategy Report 2026: JAK1, Trials and Deals
24 July 2026
2026 Ulcerative proctitis strategy: epidemiology, JAK1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…